



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

**Public Summary**

**Summary for ARTG Entry:** 342059 METAGENICS ULTRA FLORA IMMUNE CONTROL

<b>ARTG entry for</b>	Medicine Listed
<b>Sponsor</b>	Metagenics (Aust) Pty Ltd
<b>Postal Address</b>	PO Box 675, VIRGINIA BC, QLD, 4014 Australia
<b>ARTG Start Date</b>	24/08/2020
<b>Product Category</b>	Medicine
<b>Status</b>	Active
<b>Approval Area</b>	Listed Medicines

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . METAGENICS ULTRA FLORA IMMUNE CONTROL**

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	24/08/2020
---------------------	-------------------------	-----------------------	------------

**Permitted Indications**

- Maintain/support intestinal good/beneficial/friendly flora in adolescents
- Maintain/support intestinal good/beneficial/friendly flora
- Decrease/reduce/relieve symptoms of hayfever in adolescents
- Decrease/reduce/relieve symptoms of hayfever
- Helps decrease/reduce/relieve symptoms of mild allergies
  - Linked indication - Anti-inflammatory/relieve inflammation
  - Linked indication - Helps enhance/improve/promote immune system function
- Helps decrease/reduce/relieve symptoms of mild allergies in adolescents
  - Linked indication - Anti-inflammatory/relieve inflammation
  - Linked indication - Helps enhance/improve/promote immune system function
- Helps decrease/reduce/relieve symptoms of mild allergies in adolescents
- Helps decrease/reduce/relieve symptoms of mild allergies
- Decrease/reduce/relieve symptoms of allergic rhinitis in adolescents
- Decrease/reduce/relieve symptoms of allergic rhinitis
- Helps decrease/reduce/relieve symptoms of seasonal allergies
- Helps decrease/reduce/relieve symptoms of seasonal allergies in adolescents
- Helps reduce occurrence of symptoms of mild allergies in adolescents
- Helps reduce occurrence of symptoms of mild allergies
- Maintain/support immune system health
- Maintain/support immune system health in adolescents
- Maintain/support healthy immune system function
- Maintain/support healthy immune system function in adolescents

**Indication Requirements**

Label statement: If symptoms persist, talk to your health professional.

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

Product presentation must not imply or refer to serious immunological diseases.  
 Product presentation must not imply or refer to serious allergic conditions such as anaphylaxis.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist consult your healthcare practitioner (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

**Visual Identification**

**Active Ingredients**

<b>Lactobacillus paracasei</b>	<b>5 billion CFU</b>
<b>Lactobacillus rhamnosus</b>	<b>20 billion CFU</b>

**Other Ingredients (Excipients)**

- disodium edetate
- gellan gum
- hypromellose
- magnesium stearate
- maltodextrin
- microcrystalline cellulose
- potable water
- potassium acetate
- sodium ascorbate
- sucrose

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.